FSSAI vs Nestlé India: What the '5HMOs' and Whey Protein Claims Dispute Means for Infant Nutrition Buyers in 2026

India's food regulator filed three separate adjudication cases against Nestlé India on September 18, 2026, targeting two of the country's best-known infant formula brands — NAN Excella Pro Stage 1 and Lactogen Pro 1 — as well as an unnamed follow-up formula, over alleged violations of promotional-claim rules and a measurable nutritional shortfall in Biotin content.

This is only the second major regulatory confrontation between FSSAI and Nestlé India since the 2015 Maggi noodles crisis, and it directly touches the most tightly regulated product category in Indian food law: infant nutrition. For parents choosing formula in 2026, understanding what was actually alleged — and what Nestlé says in response — matters far more than the stock-market reaction.

At a Glance: The Three Products Under Scrutiny

The table below summarises the three products FSSAI examined, the specific violation alleged against each, and the applicable legal provision. All three cases were filed simultaneously on September 18, 2026.

Product	Violation Type	Specific Claim / Issue	Legal Provision Cited
NAN Excella Pro Stage 1	Promotional claim	"5HMOs" and "Whey Protein" label claims	Regulation 4(2), FSS (Foods for Infant Nutrition) Regulations 2020; Section 3, IMS Act 1992
Lactogen Pro 1	Promotional claim	"Whey Protein" described as "easy to digest"	Regulation 4(2), FSS (Foods for Infant Nutrition) Regulations 2020; Section 3, IMS Act 1992
Follow-up Formula (unnamed)	Quality / composition	Sub-standard Biotin content (confirmed by referral lab re-analysis)	FSS (Foods for Infant Nutrition) Regulations 2020 — Biotin requirement

Sources: The Hindu, Rediff / PTI, Livemint

What exactly did FSSAI find wrong with the '5HMOs' claim?

The '5HMOs' claim asserts that a formula contains five distinct Human Milk Oligosaccharides — complex carbohydrates naturally present in breast milk that are believed to support infant gut health and immune development. Nestlé has prominently featured this claim on NAN Excella Pro Stage 1 packaging and on e-commerce product listings.

FSSAI's objection is not, based on the available regulatory filings, that HMOs are absent from the product or that the science behind them is false. The objection is structural: Regulation 4(2) of the Food Safety and Standards (Foods for Infant Nutrition) Regulations, 2020 prohibits any promotional claim or material aimed at increasing the saleability of infant foods. Under this framework, even a factually accurate ingredient claim can be illegal if it functions as a sales tool rather than a neutral nutritional disclosure.

This is a deliberate policy choice rooted in the World Health Organization's International Code of Marketing of Breast-milk Substitutes, which India has incorporated into domestic law. The underlying logic is that any positive claim on infant formula packaging — however scientifically grounded — can discourage breastfeeding by making formula appear superior or specially beneficial. The IMS Act, 1992 (Infant Milk Substitutes, Feeding Bottles and Infant Foods Act) reinforces this by barring the advertisement or promotion of such products under Section 3.

Nestlé India's position is that the '5HMOs' and Whey Protein statements on NAN Excella Pro Stage 1 are "factual in nature and supported by scientific literature," and that the product and its labels were approved by the expert committee of FSSAI itself. This creates an unusual situation: the company is arguing that the regulator approved the very labels it is now prosecuting.

The tension is not unique to India. Globally, regulators are grappling with how to treat ingredient-transparency claims on infant formula — claims like "contains DHA," "with prebiotics," or "5 HMOs" — that are simultaneously informative and promotional. FSSAI's position in 2026 appears to be that the line has been crossed.

What is the Whey Protein dispute about?

The Whey Protein issue spans both products but takes a slightly different form in each. For NAN Excella Pro Stage 1, the claim is simply the presence of "Whey Protein" as a highlighted ingredient. For Lactogen Pro 1, the claim goes further: Whey Protein is described as "easy to digest," which FSSAI treats as a functional benefit claim rather than a neutral compositional statement.

Whey protein is the liquid portion of milk that separates during cheese production. In infant nutrition science it is generally considered more digestible than casein-dominant proteins because its amino acid profile and molecular structure more closely resemble human breast milk protein. Nestlé's claim, then, has a scientific basis. The regulatory problem is that making this claim on an infant formula label — even if true — constitutes promotional material under Indian law.

The distinction matters for buyers: the dispute is about labelling law, not about whether Whey Protein is actually present or whether it is genuinely easier to digest. Parents who chose these products for their Whey Protein content are not being told the ingredient is absent or harmful. They are caught in a regulatory debate about what manufacturers are allowed to say on the tin.

What is the Biotin shortfall and why does it matter more?

The Biotin finding is qualitatively different from the labelling disputes and more consequential for infant health. Biotin is a water-soluble B-vitamin (vitamin B7) that plays an essential role in fatty acid synthesis, amino acid metabolism, and gluconeogenesis — all critical processes during the rapid growth phase of infancy.

A sample of Nestlé India's follow-up formula was found sub-standard for Biotin content during laboratory analysis. The sample was then sent for re-analysis to a referral laboratory, which also found it non-conforming with the Biotin requirement prescribed under the Food Safety and Standards (Foods for Infant Nutrition) Regulations, 2020. The double confirmation — initial lab plus referral lab — is significant because it removes the possibility of a single-sample testing error.

FSSAI's 2020 regulations set minimum Biotin levels for follow-up formulas precisely because infants who rely on formula as their primary nutrition source cannot compensate for deficiencies through dietary variety the way older children and adults can. A shortfall in Biotin in a follow-up formula is a genuine nutritional compliance failure, not a labelling technicality.

Nestlé India's public response has focused on the labelling disputes and has not specifically addressed the Biotin finding in the statements reported by PTI and carried by Livemint, The Hindu, and Deccan Chronicle. The company's blanket statement that it "confirms adherence to all regulations, including all norms and label declarations as per applicable laws" covers the Biotin case implicitly, but no specific technical rebuttal of the laboratory findings has been made public as of September 19, 2026.

For parents currently using Nestlé's follow-up formula, the practical question is whether the Biotin shortfall is a batch-specific issue or a systemic formulation problem. FSSAI has not announced a product recall as of the date of publication, and the adjudication process will determine next steps. Parents with concerns should consult their paediatrician.

What are the specific laws FSSAI is invoking?

Two legal instruments are central to this case.

Regulation 4(2) of the Food Safety and Standards (Foods for Infant Nutrition) Regulations, 2020 is the primary instrument for the labelling cases. It restricts any promotional claim or material aimed at increasing the saleability of infant foods — covering packaging, e-commerce listings, and any other promotional material. This is why FSSAI specifically examined Nestlé's product pages on online platforms, not just physical packaging. The regulation reflects India's commitment to the WHO International Code and is deliberately broad in scope.

Section 3 of the Infant Milk Substitutes, Feeding Bottles and Infant Foods (Regulation of Production, Supply and Distribution) Act, 1992 — commonly called the IMS Act — bars the advertisement or promotion of infant milk substitutes and infant foods. The IMS Act predates the 2020 regulations and has historically been the primary legal tool for enforcement in this space. FSSAI cited both instruments simultaneously, signalling that the regulator is treating the violations as serious enough to warrant dual legal grounding.

The adjudication process under FSSAI involves a designated adjudicating officer who hears both sides before determining penalties. Penalties under the Food Safety and Standards Act, 2006 can range from financial fines to product bans, depending on the severity of the violation. The Biotin case, involving a confirmed compositional shortfall, carries different — and heavier — consequences than the labelling cases.

How does Nestlé India defend itself?

Nestlé India's defence rests on three pillars, all stated publicly within hours of FSSAI's announcement on September 18, 2026.

First, the company asserts that NAN Excella Pro and Lactogen Pro and their labels were approved by the expert committee of FSSAI before they went to market. If accurate, this raises a legitimate procedural question: can FSSAI prosecute a company for labels the regulator's own expert committee approved?

Second, Nestlé argues that the statements on the labels are "factual in nature and supported by scientific literature" — a substantive scientific defence. The company is not conceding that the claims are misleading, only that they accurately describe the product's composition and the properties of its ingredients.

Third, the company says it has "again submitted its detailed response to the authorities regarding statements appearing on the label." The word "again" suggests an ongoing regulatory dialogue rather than a sudden enforcement action.

Whether these defences will prevail in adjudication is uncertain. The prior-approval argument is legally interesting but not necessarily decisive — regulators can change their interpretation of rules, and a committee approval does not automatically immunise a company from subsequent enforcement. The scientific-accuracy argument faces the structural problem that Indian infant nutrition law does not require a claim to be false to be illegal; it requires only that the claim functions as a promotional tool.

How does this compare to the 2015 Maggi crisis?

This is the second major regulatory dispute between FSSAI and Nestlé India, the first being the 2015 Maggi noodles crisis in which FSSAI ordered a nationwide recall over alleged excessive lead levels and labelling concerns. The Maggi ban was subsequently lifted after tests by authorised laboratories cleared the product.

The two cases differ in important ways. The Maggi crisis involved a safety-critical contaminant in a mass-market product consumed by hundreds of millions of people across all age groups, triggering a complete product recall. The 2026 infant formula case involves labelling law violations and a single confirmed nutritional shortfall in a product consumed by a much smaller, more vulnerable population — infants who cannot supplement their diet from other sources.

The regulatory stakes in the 2026 case are higher on a per-consumer basis precisely because the affected population is infants. But the commercial and reputational scale of the Maggi crisis — which wiped billions from Nestlé India's market capitalisation and took months to resolve — has not been replicated here. Shares of Nestlé India fell approximately 1.4–2% on September 18, 2026, a significant single-day move but far from the existential threat the Maggi ban represented.

What should parents and buyers actually do right now?

The practical implications for parents currently using Nestlé infant formula products in India depend on which product they are using and why.

For parents using NAN Excella Pro Stage 1 or Lactogen Pro 1, the FSSAI action relates to labelling claims — not to the safety or efficacy of the product itself. There is no recall, no contamination alert, and no suggestion that the products are harmful. The dispute is about whether the manufacturer was legally permitted to make certain statements on the packaging. Both products remain on the market as of September 19, 2026.

For parents using Nestlé's follow-up formula (the specific product has not been publicly named in available reports), the Biotin shortfall is a more substantive concern. Biotin deficiency in infants can manifest as skin rashes, hair loss, and neurological symptoms, though the severity of any deficiency would depend on the magnitude of the shortfall and the duration of use. FSSAI has not issued a recall or a public health advisory beyond the adjudication filing. Parents using a Nestlé follow-up formula should speak with their paediatrician about whether to continue use while the adjudication proceeds, and should monitor FSSAI's official channels for updated guidance.

More broadly, this case is a reminder that e-commerce product listings for infant formula — which FSSAI specifically examined in this investigation — can carry claims that have not been updated to reflect current regulatory interpretations. Buyers who rely on online listings to compare products may be reading promotional content the regulator considers non-compliant.

The Biotin finding also connects to a broader conversation about micronutrient adequacy in infant formula. Biotin is one of several B-vitamins whose minimum levels are specified in the 2020 regulations, and the fact that a referral laboratory confirmed the shortfall on re-analysis suggests the gap was not marginal. For a deeper look at Biotin's biochemical role — including its function in skin and metabolic health — see our coverage of best biotin supplements for skin health.

What does this mean for the broader infant nutrition market in India?

The FSSAI action against Nestlé India sends a clear signal to the entire infant nutrition industry: the regulator is actively monitoring e-commerce platforms, not just physical retail, and it is prepared to treat ingredient-transparency claims as promotional violations even when those claims are scientifically accurate.

For competing brands — Abbott's Similac, Danone's Aptamil, and domestic players like Amul — this creates both a compliance challenge and a market opportunity. Any brand that has used similar HMO, DHA, or protein-quality claims on its packaging or online listings now faces the same regulatory exposure that Nestlé is navigating. The 2020 regulations apply uniformly across the category.

The case also highlights a genuine policy tension that FSSAI will eventually need to resolve. Parents who cannot breastfeed, or who supplement breastfeeding with formula, have a legitimate interest in understanding what is in the products they are buying. Ingredient transparency and promotional restriction are not always easy to reconcile, and the regulatory framework has not yet drawn a clear bright line between a neutral compositional disclosure and a prohibited sales claim.

The adjudication process will likely produce some clarification on where that line sits, at least for HMO claims and protein-digestibility statements. Every infant nutrition manufacturer operating in India will be watching the outcome closely.

For context on how micronutrient standards interact with supplement regulation more broadly in India, our article on berberine for insulin resistance and blood sugar illustrates how Indian regulatory frameworks handle evidence-based ingredient claims in adjacent categories — a useful frame for understanding why FSSAI takes a conservative stance on health claims even when the underlying science is solid.

What is the timeline and what happens next?

As of September 19, 2026, FSSAI has filed three separate adjudication cases against Nestlé India. The adjudication process under the Food Safety and Standards Act, 2006 involves a designated adjudicating officer who hears both parties before issuing a ruling. There is no mandatory public timeline, and cases can take months to resolve.

Nestlé India has already submitted a detailed response to the authorities and indicated it will "continue to work closely and support FSSAI in its efforts towards consumer awareness" — language that suggests a cooperative engagement strategy rather than a confrontational one, consistent with how the company handled its post-Maggi recovery.

Key milestones to watch:

Whether FSSAI issues a product recall or public health advisory for the follow-up formula with the Biotin shortfall
Whether the adjudicating officer accepts Nestlé's prior-approval defence for the labelling cases
Whether FSSAI issues broader industry guidance clarifying which ingredient claims are permissible on infant formula packaging and e-commerce listings
Whether other infant nutrition brands proactively revise their own labels in response to this enforcement action

The data available as of publication does not allow a confident prediction of the adjudication outcome. What is clear is that the case has already prompted a regulatory conversation about the boundary between information and promotion in one of India's most sensitive food categories — and that conversation will shape what parents see on infant formula packaging for years to come.